Peter Slavin has been a visionary leader for MGH and a tremendous ally to the biomedical research community.
After his 18 years of humble leadership and a career of service, our initial disappointment quickly fades to gratitude. We wish him well and hope to build on his legacy.
Peter Slavin, president of Massachusetts General Hospital, plans to retire after 18 years leading the prestigious institution http://bos.gl/e1UgVKp
New analyses of rare CNVs from 750K individuals to identify dosage sensitive loci across 30 disorders.
Long-term commitment from the incomparable @RyanLCollins13 and team @CGM_MGH @Harvardmed @broadinstitute to aggregate data collected over a decade to derive new insights. 👇
🚨🔊New @medrxivpreprint from @TalkowskiLab🔊🚨
Interested in rare copy-number variants (rCNVs), disease, or dosage sensitivity?
We aggregated rCNVs in ~750k individuals to build genome-wide maps of dosage sensitivity across 30 disorders:
https://www.medrxiv.org/content/10.1101/2021.01.26.21250098v1
🧵👇
1/8
Come join the faculty and genomics communities of @CGM_MGH @Harvardmed @MGH_RI @BroadInstitute!! This is an open search in all areas of genomic medicine relevant to the CGM mission. See our faculty and research programs here: https://cgm.massgeneral.org/
Final call for applications to our @Harvardmed Faculty Search! This is an open Assistant/Associate Professor search within @CGM_MGH @MGH_RI for research programs across all areas of genomic medicine. See http://cgm.massgeneral.org for details. Due Feb 1, 2021.
The scientific community just collectively exhaled - @JoeBiden approach:
-Ask 5 big questions
https://buildbackbetter.gov/wp-content/uploads/2021/01/OSTP-Appointment.pdf
-Find a leader @eric_lander @broadinstitute
-Assemble a stellar team @maria_zuber @NIHDirector et al.
-Provide structural support (cabinet)
-Solve problems